AUSTIN, Texas, April 8, 2019 /PRNewswire-PRWeb/ -- POTENTIAMETRICS, an Austin, TX based healthcare data and artificial intelligence company, announced the addition of Jonathan Heinlen, M.D. and Tara Kaufmann, M.D. to the ranks of its stellar advisory board of specialists, MDs and medical researchers.
MyCancerJourney was developed by researchers at Washington University in St. Louis School of Medicine to provide patient-specific survival estimates and empower patients.
Dr. Heinlen stated, "I'm thrilled to be a part of an innovative company that is finding solutions for patients that empowers them with easy to understand data to make more informed decisions about their cancer treatment."
Dr. Heinlen is a board certified urologist with fellowship training in Urologic Oncology and minimally invasive surgery. He specializes in treatment of urologic cancers, with a particular focus on prostate and kidney cancer. In addition to cancer, Dr. Heinlen offers minimally invasive solutions for complicated urinary stone disease and benign prostatic hypertrophy. Dr. Heinlen elected to pursue medical training at the University of Oklahoma and continued on in urology residency in Oklahoma. He then trained at the City of Hope National Cancer Center in Los Angeles.
Dr. Heinlen has a particular interest in improving the way physicians interact with their patients to create better healthcare outcomes. This includes a focus on cost-efficiency, patient-centered decision making, and evidence-based practice. Dr. Heinlen has ongoing research studies in urologic clinical practice and also participates in multiple cancer trials.
In addition to Dr. Heinlen, Tara Kaufmann, M.D. joins the Clinical Advisory Board. Dr. Kaufmann completed her undergraduate education in Biochemistry at the University of Pennsylvania. She sub-matriculated during her undergraduate years to also complete a Masters Degree in Chemistry. She received her medical degree at the University of California –San Francisco and completed residency in internal medicine at the University of North Carolina. She then completed a palliative care fellowship at Duke before moving back to UPenn for a fellowship in Hematology/Oncology. Her research interest is in patient-reported outcomes and advanced analytics in aiding treatment decisions and targeting supportive care services for patients diagnosed with cancer.
Dr. Kaufmann stated, "I'm excited to be a part of a company that's using advanced analytics and AI to address the challenges we face in treating newly diagnosed patients with cancer. There are many unknowns we can address at the patient level with the MyCancerJourney platform that cannot be addressed through conventional clinical trials."
"We are quite pleased to have both Dr. Heinlen and Dr. Kaufmann as members of our Clinical Advisory Board. Their areas of specialty and research add to the breadth and depth of the board's multi-disciplinary experiences," noted Robert Palmer, CEO of PotentiaMetrics.
About PotentiaMetrics
PotentiaMetrics develops unique outcomes and insights solutions to support more informed, value-based treatment decisions that lead to better outcomes and reduced costs.
To learn more about PotentiaMetrics, visit: http://www.potentiametrics.com
To learn more about MyCancerJourney, visit: http://www.mycancerjourney.com
SOURCE PotentiaMetrics
Share this article